At the 2018 PDA Cell and Gene Therapy Conference, Oct. 23-24, gain insight and hear real life examples from industry and regulatory experts on the current innovation and advancements helping to push the field of cell and gene therapy forward.

Take advantage of the ideal forum in which to share best practices for successfully stewarding these advanced therapies toward approval and beyond.

Plenary sessions will feature exciting topics such as:

• Navigating the Progress and Promise of Gene Editing
• Quality and Manufacturing Challenges in Cell and Gene Therapy
• Automation of Cell Therapy Product Manufacturing
• Regulatory Considerations for Development and Commercialization of Cell and Gene Therapies
• Expert Panel Discussion Exploring the Current State of the Industry, Regulatory Insight, and Practical Questions

Here are some of the confirmed experts who will present at this year’s Conference:

• Gregory Block, PhD, VP Corporate Development, Universal Cells Inc.
• Peter Hoang, President & Chief Executive Officer, TapImmune, Inc.
• Anna Kwilas, PhD, Product CMC Reviewer, CBER, U.S. FDA
• Sheng Lin-Gibson, PhD, Chief, Biosystems and Biomaterials Division, NIST
• Peter Marks, MD, PhD, Director, CBER, U.S. FDA
• Patrick P. Pezzoli, Director, Product Characterization, Inovio Pharmaceuticals

You don’t want to miss out on this exceptional Conference!